21
Participants
Start Date
January 31, 2003
Primary Completion Date
March 31, 2003
Study Completion Date
May 31, 2003
Non-invasive CGMS (continuous glucose monitoring system)
A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
Hyperglycemic and hypoglycemic glucose clamp
The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
Non-invasive CGMS (GlucoDay)
The minimally-invasive glucose sensor GlucoDay, was used as a control measure
Profil Institut für Stoffwechselforschung GmbH, Neuss
Pendragon Medical AG Switzerland
UNKNOWN
Profil Institut für Stoffwechselforschung GmbH
INDUSTRY